Cellectis SA
(OTCPK:CMVLF)
$
3.47
(0%)
Market Cap: 275.30 Mil
Enterprise Value: 183.39 Mil
PE Ratio: 0
PB Ratio: 4.79
GF Score: 59/100 Cellectis SA at Citi Biotech Conference Transcript
Sep 04, 2019 / 05:30PM GMT
Release Date Price:
$11.29
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
The next panel is cell therapy, up-and-comers in the cell therapy space. So it's my pleasure to introduce our 3 distinguished guests, from Atara the CEO, Pascal Touchon; and from Cellectis, André Choulika; and, of course, from Fate, in the middle, Scott Wolchko. So welcome all of you. Thanks for making the time.
Questions & Answers
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
I guess the question I have to start out the session is at a 30,000-foot level, could each of you give your thoughts on what are the ingredients to create a successful cell therapy? What are the things you want to do? And what are the things that you absolutely want to avoid on the path to a product that's a cell-based therapy? So you want to kick it off, Pascal?
Pascal Touchon;Yigal Dov Nochomovitz<
Atara Biotherapeutics, Inc. - President, CEO & Director
Yes, with pleasure. I mean thank you for inviting me, by the way.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot